Bosuvi 400 mg Tablet is an anti-cancer medicine used in the treatment of Leukemia. Leukemia, also known as blood cancer, is a cancer of blood cells or blood-forming tissues. It causes excessive production of immature white blood cells by the bone marrow and reduces the body’s ability to fight infections. Bosuvi 400 mg Tablet is used in the treatment of chronic myelogenous leukemia (CML). This medicine is used in patients with chronic, accelerated, or blast phase Ph+ (Philadelphia chromosome-positive) chronic myelogenous leukemia who are resistant or intolerant to prior therapy.

Bosuvi 400 mg Tablet contains Bosutinib, which belongs to the class of kinase inhibitors. It works by inhibiting the action of abnormal proteins that cause the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other parts of the body.

Bosuvi 400 mg Tablet may cause certain side effects, such as rash, fatigue, headache, back pain, decreased platelet count, back pain, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, and dizziness. These side effects do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor. Bosuvi 400 mg Tablet should be taken as advised by your doctor. Do not take more than the recommended dose of medicine. Your doctor will decide the dose of Bosuvi 400 mg Tablet based on the severity of your condition.

Bosuvi 400 mg Tablet should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before taking this medicine, inform your doctor if you have liver/kidney disease, gastrointestinal toxicity, myelosuppression, fluid retention, and hepatic toxicity, as may cause serious side effects or worsen such conditions. This medicine is known to cause embryo-fetal toxicity. Hence, inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment with Bosuvi 400 mg Tablet . Breastfeeding should be discontinued in nursing mothers during the treatment. Bosuvi 400 mg Tablet is not recommended for use in children below 18 years of age as the safety and efficacy are not established.

Bosuvi 400 mg Tablet contains Bosutinib, which belongs to the class of kinase inhibitors. It works by inhibiting the action of abnormal proteins that cause the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other parts of the body.

Bosuvi 400 mg Tablet should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before taking, inform your doctor if you have liver/kidney disease, diabetes, cardiac problems, increased blood pressure, gastrointestinal toxicity, myelosuppression, fluid retention, and hepatic toxicity, as the use of Bosuvi 400 mg Tablet in these patients may cause serious side effects. This medicine is known to cause embryo-fetal toxicity. Hence, inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment. Breastfeeding should be discontinued in nursing mothers during the treatment. Bosuvi 400 mg Tablet is not recommended for use in children below 18 years of age as the safety and efficacy are not established. Avoid alcohol consumption and smoking, as it can lead to serious adverse effects.

• Bosuvi 400 mg Tablet should be administered only by a trained and experienced oncologist.
• A blood test should be performed such as LFT and RFT, to check for liver/kidney function.
• Weekly blood tests should be done during the treatment to check for CBC (Complete blood count).